SmallCaps
ASX:BB1Health Care Equipment & ServicesHealth Care Technology

BlinkLab Ltd

$0.855
Day Range
$0.845 – $0.865
52 Week Range
$0.510 – $1.105
Volume
72.30K
Avg Volume (10D)
426.14K
Market Cap
$131.04M

Price Chart

OHLC · volume · moving averages

$0.855-$0.060 (-6.56%)over 6M
Hi$0.940Lo$0.560
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.855
Previous Close
$0.855
Day High
$0.865
Day Low
$0.845
52 Week High
$1.105
52 Week Low
$0.510

Valuation

Fundamental multiples

Market Cap
131.04M
Shares Outstanding
153.26M
Price to Book
6.82

Trading Activity

Volume & order book

Volume
72.30K
Value Traded
61.77K
Bid
$0.855 × 18,299
Ask
$0.860 × 21,887

Performance

Returns across timeframes

1 Day
-1.69%
5 Day
29.85%
13 Week
24.29%
52 Week
79.38%
YTD
7.41%

Technical Indicators

Momentum & moving averages

RSI (14)
64.62
50-Day SMA
$0.677
200-Day SMA
$0.776

— From the desk

Latest News

BlinkLab Dx 1 Device Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial
Technology

BlinkLab Dx 1 Device Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial

BlinkLab (ASX: BB1) has completed a US pilot study evaluating the smartphone-based Dx 1 diagnostic device for the assessment of behavioural and developmental concerns in children, including autism spectrum disorder and attention deficit hyperactivity disorder. The unblinded study involved 485 clinically-diverse children aged between 2 years and 11 years, representing the full spectrum of developmental concerns, […]

BlinkLab partners with INTER-PSY to improve wait times for autism diagnosis in children
Technology

BlinkLab partners with INTER-PSY to improve wait times for autism diagnosis in children

Digital healthcare company BlinkLab (ASX: BB1) has formed a research and clinical partnership with Netherlands-based INTER-PSY to improve wait times for autism diagnosis in children. INTER-PSY offers mental health care, guidance and diagnosis to children and adults with psychological and psychiatric conditions. The partnership will support the adoption of BlinkLab as a diagnostic tool within […]

BlinkLab to advance smartphone-neurobehavioural testing following IPO and ASX debut
Technology

BlinkLab to advance smartphone-neurobehavioural testing following IPO and ASX debut

Neuroscientist-led start-up BlinkLab (ASX: BB1) has made its Australian Securities Exchange (ASX) debut today after an oversubscribed initial public offering raised $7 million to advance a diagnostic tool for neurodevelopmental disorders. The company has committed to the issue of 35 million shares at $0.20 each for an undiluted market capitalisation of $19.8m on listing. The […]